AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Japanese Encephalitis Vaccine Market Report and Forecast to 2026 - ResearchAndMarkets.com

July 22, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Jul 22, 2021--

The “Global JE (Japanese Encephalitis) Vaccine Market Report and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering.

According to this report the global JE (Japanese encephalitis) vaccine market is projected to further grow at a CAGR of 5.9% between 2021 and 2026.

The Japanese encephalitis (JE) vaccine is an inactivated vaccine that protects against Japanese encephalitis, a brain infection caused by the Japanese encephalitis virus (JEV), which is carried mostly by mosquitos. Over the forecast period, the worldwide Japanese encephalitis vaccine market is expected to develop at a healthy rate. According to the World Health Organization, the yearly number of clinical cases of JE is predicted to be around 68,000 worldwide. Increased travel and tourism, a government push to eradicate the illness, pig farming, the arrival of new vaccine makers, and increased R&D are some of the other drivers driving the growth of this industry. The global JE (Japanese encephalitis) vaccine market is also growing because of rising mosquito annoyance, more awareness, and increased expenditure in the healthcare sector by governments throughout the world.

ADVERTISEMENT

The global need for JE (Japanese encephalitis) vaccines is increasing as the frequency and incidence of Japanese encephalitis illness rises. The market is seeing a considerable demand for JE (Japanese encephalitis) vaccines as a result of the expanding trend of routine immunization or vaccination. Furthermore, governments across the country are projected to include Japanese encephalitis vaccine in national immunization programs, which is predicted to be one of the industry’s major growth drivers throughout the forecast period. The industry’s expansion is being aided by increased investment in vaccine R&D. China and India are particularly vulnerable to Japanese encephalitis in the Asia Pacific. As a result, the governments of these countries are administering mass vaccinations, giving the sector a boost. Lack of knowledge, on the other hand, may stymie market expansion throughout the projection period.

Market Segmentation

The market report analyses the market based on segmentations such as type, distribution channel, and major regions.

Market Breakup by Type:

  • Inactivated Vaccines
  • Recombinant Vaccines
  • Live attenuated Vaccines

Market Segmentation by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Market Breakup by Region:

ADVERTISEMENT

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the key players in the industry.

Some of the major players in the market explored in the report are:

  • Valneva SE (EPA: VLA)
  • Bharat Biotech,
  • Sanofi SA
  • Chengdu Institute of Biological Product

Key Topics Covered:

1 Preface

2 Research Methodology

3 Introduction

4 Executive Summary

4.1 Key Market Developments

4.2 Market Analysis

4.3 Key Players

4.4 Cost Structure

4.5 Market Revenue and Growth

5 Market Dynamics

5.1 Market Driver Analysis

5.2 Market Restraint Analysis

5.3 Industry Challenges

5.4 Industry Opportunities

6 Global JE (Japanese Encephalitis) Vaccine Market Analysis

7 SWOT Analysis

7.1 Overview

7.2 Strengths

7.3 Weaknesses

7.4 Opportunities

7.5 Threats

8 Porter’s Five Forces Analysis

8.1 Overview

8.2 Buyer’s Power

8.3 Supplier’s Power

8.4 New Entrants

8.5 Degree of Rivalry

8.6 Substitutes

9 Competitive Landscape & Supplier Analysis

9.1 Valneva SE (EPA: VLA)

9.1.1 Company Overview

9.1.2 Financial Analysis

9.2 Bharat Biotech,

9.2.1 Company Overview

9.2.2 Financial Analysis

9.3 Sanofi SA

9.3.1 Company Overview

9.3.2 Financial Analysis

9.4 Chengdu Institute of Biological Products

9.4.1 Company Overview

9.4.2 Financial Analysis

9.5 Others

10 Industry Events and Developments

For more information about this report visit https://www.researchandmarkets.com/r/ldrhrw

View source version on businesswire.com:https://www.businesswire.com/news/home/20210722005682/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: INFECTIOUS DISEASES PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 07/22/2021 10:03 AM/DISC: 07/22/2021 10:04 AM

http://www.businesswire.com/news/home/20210722005682/en